Octagon Capital Advisors LP Grows Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX)

Octagon Capital Advisors LP grew its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 62.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,304,752 shares of the company's stock after purchasing an additional 882,528 shares during the period. Perspective Therapeutics makes up about 1.2% of Octagon Capital Advisors LP's investment portfolio, making the stock its 25th largest position. Octagon Capital Advisors LP owned approximately 3.41% of Perspective Therapeutics worth $7,352,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Y Intercept Hong Kong Ltd bought a new position in Perspective Therapeutics during the fourth quarter worth $33,000. Aigen Investment Management LP acquired a new stake in shares of Perspective Therapeutics during the 4th quarter worth approximately $34,000. National Bank of Canada FI lifted its holdings in shares of Perspective Therapeutics by 549,900.0% in the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock worth $35,000 after purchasing an additional 10,998 shares during the last quarter. Vontobel Holding Ltd. acquired a new position in Perspective Therapeutics during the 4th quarter valued at approximately $51,000. Finally, Mercer Global Advisors Inc. ADV acquired a new stake in Perspective Therapeutics in the fourth quarter worth $51,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Perspective Therapeutics

In other news, Director Robert F. Williamson III purchased 22,192 shares of the business's stock in a transaction dated Friday, March 28th. The shares were bought at an average cost of $2.27 per share, for a total transaction of $50,375.84. Following the completion of the acquisition, the director now directly owns 70,837 shares in the company, valued at approximately $160,799.99. This trade represents a 45.62% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Juan Graham acquired 33,333 shares of the stock in a transaction dated Friday, March 28th. The stock was acquired at an average price of $2.25 per share, for a total transaction of $74,999.25. Following the completion of the acquisition, the chief financial officer now directly owns 35,354 shares of the company's stock, valued at $79,546.50. The trade was a 1,649.33% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 115,696 shares of company stock worth $256,344. Company insiders own 3.72% of the company's stock.

Analysts Set New Price Targets

CATX has been the topic of several recent research reports. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Tuesday, March 4th. Truist Financial lowered their target price on Perspective Therapeutics from $21.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday, April 7th. Royal Bank of Canada decreased their price target on Perspective Therapeutics from $16.00 to $15.00 and set an "outperform" rating for the company in a research note on Thursday, March 27th. Wedbush restated an "outperform" rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research note on Wednesday, March 26th. Finally, Lifesci Capital upgraded shares of Perspective Therapeutics to a "strong-buy" rating in a research report on Thursday, March 6th. One analyst has rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $12.75.

Perspective Therapeutics Price Performance

Shares of CATX opened at $2.51 on Tuesday. The business's 50 day simple moving average is $2.26 and its 200-day simple moving average is $3.85. Perspective Therapeutics, Inc. has a one year low of $1.60 and a one year high of $19.05.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.